CoChat
Sign Up
Cited by 176Per- and polyfluoroalkyl substances researchMetabolomics and Mass Spectrometry StudiesPeroxisome Proliferator-Activated Receptors

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Dysregulated lipid and fatty acid metabolism link perfluoroalkyl substances exposure and impaired glucose metabolism in young adults

Open access
Chen, Zhanghua, Yang, Tingyu, Walker, Douglas I., Thomas, Duncan C., Qiu, Chenyu, Chatzi, Leda, Alderete, Tanya L., Kim, Jeniffer S., Conti, David V., Breton, Carrie V., Liang, Donghai, Hauser, Elizabeth R., Jones, Dean P., Gilliland, Frank D.·2020·Environment International
DOI 10.1016/j.envint.2020.106091PMC PMC8009052
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Per- and polyfluoroalkyl substances (PFASs) exposure is ubiquitous among the US population and has been linked to adverse health outcomes including cardiometabolic diseases, immune dysregulation and endocrine disruption. However, the metabolic mechanism underlying the adverse health effect of PFASs exposure is unknown. OBJECTIVE: The aim of this project is to investigate the association between PFASs exposure and altered metabolic pathways linked to increased cardiometabolic risk in young adults. METHODS: A total of 102 young adults with 82% overweight or obese participants were enrolled from Southern California between 2014 and 2017. Cardiometabolic outcomes were assessed including oral glucose tolerance test (OGTT) measures, body fat and lipid profiles. High-resolution metabolomics was used to quantify plasma exposure levels of three PFAS congeners and intensity profiles of the untargeted metabolome. Fasting concentrations of 45 targeted metabolites involved in fatty acid and lipid metabolism were used to verify untargeted metabolomics findings. Bayesian Kernel Machine Regression (BKMR) was used to examine the associations between PFAS exposure mixture and cardiometabolic outcomes adjusting for covariates. Mummichog pathway enrichment analysis was used to explore PFAS-associated metabolic pathways. Moreover, the effect of PFAS exposure on the metabolic network, including metabolomic profiles and cardiometabolic outcomes, was investigated. RESULTS: Higher exposure to perfluorooctanoic acid (PFOA) was associated with higher 30-minute glucose levels and glucose area under the curve (AUC) during the OGTT (p < 0.001). PFAS exposure was also associated with altered lipid pathways, which contributed to the metabolic network connecting PFOA and higher glucose levels following the OGTT. Targeted metabolomics analysis indicated that higher PFOA exposure was associated with higher levels of glycerol (p = 0.006), which itself was associated with higher 30-minute glucose (p = 0.006). CONCLUSIONS: Increased lipolysis and fatty acid oxidation could contribute to the biological mechanisms linking PFAS exposure and impaired glucose metabolism among young adults. Findings of this study warrants future experimental studies and epidemiological studies with larger sample size to replicate.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.envint.2020.106091

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Associations of perfluoroalkyl substances (PFASs) exposure mixture with 30-minute glucose levels and glucose area under the curve (AUC) measured during the oral glucose tolerance test (OGTT). Panels A) and B) present total effects of PFAS exposure mixture on glucose outcomes by quantiles of exposure levels. Panels C) and D) present differences of glucose outcomes in participants with individual PFAS chemical exposure [perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS) and perfluorohexane sulfonic acid (PFHxS)] level at 90th percentile to participants with the exposure level at 10th percentile, while conditioned on the other two PFAS chemical exposures both at 50th percentiles across all participants.
Fig. 1. Associations of perfluoroalkyl substances (PFASs) exposure mixture with 30-minute glucose levels and glucose area under the curve (AUC) measured during the oral glucose tolerance test (OGTT). Panels A) and B) present total effects of PFAS exposure mixture on glucose outcomes by quantiles of exposure levels. Panels C) and D) present differences of glucose outcomes in participants with individual PFAS chemical exposure [perfluorooctanoic acid (PFOA), perfluorooctane sulfonate (PFOS) and perfluorohexane sulfonic acid (PFHxS)] level at 90th percentile to participants with the exposure level at 10th percentile, while conditioned on the other two PFAS chemical exposures both at 50th percentiles across all participants.CC BY-NC-ND · PubMed Central
Fig. 2. Metabolic pathways that are associated with PFAS exposures revealed by the analysis of high-resolution metabolomics data (metabolomic features having coefficients of variation ≤ 0.3 across 5 analytical batches) from fasting and 30-minute post glucose challenge plasma samples using both HILIC positive and C18 negative modes. The horizontal scale indicates the significance levels of pathway enrichment tests conducted by Mummichog software.
Fig. 2. Metabolic pathways that are associated with PFAS exposures revealed by the analysis of high-resolution metabolomics data (metabolomic features having coefficients of variation ≤ 0.3 across 5 analytical batches) from fasting and 30-minute post glucose challenge plasma samples using both HILIC positive and C18 negative modes. The horizontal scale indicates the significance levels of pathway enrichment tests conducted by Mummichog software.CC BY-NC-ND · PubMed Central
Fig. 3. Integrated network analysis among PFAS exposures, metabolites with confirmed identity and multiple cardiometabolic outcomes including adiposity measures, oral-glucose tolerance test-derived glucose and insulin measures, insulin resistance index and lipid profiles. Each PFAS exposure, metabolite and outcome variable is treated as a node in the entire network and are plotted using different shapes. Sub-networks are classified by different colors and represent more connections between specific PFAS congener with a group of metabolomic signatures and cardiometabolic outcomes. Panel A presents the network among PFAS exposure, metabolite intensity in fasting plasma samples and cardiometabolic outcomes. Panel B presents the network among PFAS exposure, metabolite intensity in 30-minute post glucose challenge plasma samples and cardiometabolic outcomes. PFAS exposures: PFOA = Perfluorooctanoic acid; PFOS = Perfluorooctane sulfonate; PFHxS = Perfluorohexane sulfonic acid. Metabolites: LysoPC = LysoPC (18:0); FA8:0 = FA 8:0 (Octanoate); FA16:0 = FA 16:0 (Palmitate); FA18:3 = FA 18:3n-3 or n-6 (Linolenic acid); FA18:2 = FA 18:2 (Linoleic acid); FA18:1 = FA 18:1 (Oleic acid); FA18:0 = FA 18:0 (Stearic acid); FA20:4 = FA 20:4 (Arachidonic acid); FA20:3 = FA 20:3 (Homolinoleic acid); Sph = Sphingosine; Cit = Citrulline; Met = Methionine; Glu = Glucose; Man = Mannose/Galactose; Lac = Lactate; Gln = Glutamine; HMG = Hydroxymethylglutarate; KIV = Oxovalerate/Ketoisovalerate. Cardiometabolic outcomes: 30-min GLU = 30-min glucose after OGTT; 2-hr GLU = 2-hour glucose after OGTT; Glu AUC = OGTT glucose area under the curve; Fasting Ins = Fasting insulin; 30-min Ins = 30-min insulin after OGTT; 2-hr Ins = 2-hour insulin after OGTT; Ins AUC = OGTT insulin area under the curve; HFF = Hepatic fat fraction; HOMA-β = Homeostatic model assessment β-cell function; Matsuda = Matsuda index; HOMA-IR = Homeostatic model assessment insulin resistance; SAAT = Subcutaneous adipose tissue; BMI = Body mass index; Body fat % = Body fat percent; VAT = Visceral adipose tissue; VAT/SAAT = VAT-to-SAAT ratio; LDL = Low-density lipoprotein.
Fig. 3. Integrated network analysis among PFAS exposures, metabolites with confirmed identity and multiple cardiometabolic outcomes including adiposity measures, oral-glucose tolerance test-derived glucose and insulin measures, insulin resistance index and lipid profiles. Each PFAS exposure, metabolite and outcome variable is treated as a node in the entire network and are plotted using different shapes. Sub-networks are classified by different colors and represent more connections between specific PFAS congener with a group of metabolomic signatures and cardiometabolic outcomes. Panel A presents the network among PFAS exposure, metabolite intensity in fasting plasma samples and cardiometabolic outcomes. Panel B presents the network among PFAS exposure, metabolite intensity in 30-minute post glucose challenge plasma samples and cardiometabolic outcomes. PFAS exposures: PFOA = Perfluorooctanoic acid; PFOS = Perfluorooctane sulfonate; PFHxS = Perfluorohexane sulfonic acid. Metabolites: LysoPC = LysoPC (18:0); FA8:0 = FA 8:0 (Octanoate); FA16:0 = FA 16:0 (Palmitate); FA18:3 = FA 18:3n-3 or n-6 (Linolenic acid); FA18:2 = FA 18:2 (Linoleic acid); FA18:1 = FA 18:1 (Oleic acid); FA18:0 = FA 18:0 (Stearic acid); FA20:4 = FA 20:4 (Arachidonic acid); FA20:3 = FA 20:3 (Homolinoleic acid); Sph = Sphingosine; Cit = Citrulline; Met = Methionine; Glu = Glucose; Man = Mannose/Galactose; Lac = Lactate; Gln = Glutamine; HMG = Hydroxymethylglutarate; KIV = Oxovalerate/Ketoisovalerate. Cardiometabolic outcomes: 30-min GLU = 30-min glucose after OGTT; 2-hr GLU = 2-hour glucose after OGTT; Glu AUC = OGTT glucose area under the curve; Fasting Ins = Fasting insulin; 30-min Ins = 30-min insulin after OGTT; 2-hr Ins = 2-hour insulin after OGTT; Ins AUC = OGTT insulin area under the curve; HFF = Hepatic fat fraction; HOMA-β = Homeostatic model assessment β-cell function; Matsuda = Matsuda index; HOMA-IR = Homeostatic model assessment insulin resistance; SAAT = Subcutaneous adipose tissue; BMI = Body mass index; Body fat % = Body fat percent; VAT = Visceral adipose tissue; VAT/SAAT = VAT-to-SAAT ratio; LDL = Low-density lipoprotein.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 2

  1. Salihovic, 2018, Identification of metabolic profiles associated with human exposure to perfluoroalkyl substances, J. Expo Sci. Environ. Epidemiol.
  2. Patsouris, 2004, PPARalpha governs glycerol metabolism, J. Clin. Invest., 114, 94, 10.1172/JCI200420468 · DOI

Cited by

Sorted by citations

See all 176

Related

Metadata

Authors
Chen, Z., Yang, T., Walker, D. I., Thomas, D. C., Qiu, C., Chatzi, L., Alderete, T. L., Kim, J. S., Conti, D. V., Breton, C. V., Liang, D., Hauser, E. R., Jones, D. P., & Gilliland, F. D.
Affiliations
  • University of Southern California (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • University of Colorado Boulder (US)
  • Emory University (US)
  • Duke University (US)
Corresponding author
Chen, Zhanghua
ORCID
Venue
Environment International
Publisher
Elsevier BV
Published
2020-12
Volume
145
Pages
106091
ISSN
0160-4120 (ISSN-L)
DOI
10.1016/j.envint.2020.106091
PMC
PMC8009052
OpenAlex
W3083268731
Cited by
176
References
47
Citations by year
2026: 25 · 2025: 39 · 2024: 33 · 2023: 33 · 2022: 27 · 2021: 18 · 2020: 1
FWCI
7.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Environment International (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of Environmental Health Sciences
  • U.S. Environmental Protection Agency
Topics
  • Physical Sciences › Environmental Science › Environmental Chemistry › Per- and polyfluoroalkyl substances research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
per- and polyfluoroalkyl substances, PFAS exposure, perfluorooctanoic acid, impaired glucose metabolism, lipid metabolism, fatty acid metabolism, glycerol, lipolysis, fatty acid oxidation, cardiometabolic risk, young adults, obesity, oral glucose tolerance test, plasma metabolome
MeSH terms
Bayes Theorem, Environmental Pollutants, Fatty Acids, Fluorocarbons, Glucose, Humans, Lipids, Alkanesulfonic Acids, Lipid Metabolism, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review